[Leading drugs in 1995: success, failures and uncertainties].
Presentation of drugs most worthy of interest in autumn 1995. Among these, the ACE inhibitors, the HMGCOA inhibitors, the Proton Pump inhibitors, the serotoninergics used against depression and migraine, the endobronchial corticoids and finally the ASA. Review of their successes, failures and uncertainties.
D000287:Administration, Topical; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000627:therapeutic use; D004358:Drug Therapy; D005938:Glucocorticoids; D006801:Humans; D004364:Pharmaceutical Preparations; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D000893:Anti-Inflammatory Agents; D000924:Anticholesteremic Agents; D001241:Aspirin; D001562:Benzimidazoles; D001993:Bronchodilator Agents; D005938:Glucocorticoids; D004364:Pharmaceutical Preparations; D017366:Serotonin Receptor Agonists; D017367:Selective Serotonin Reuptake Inhibitors
Les médicaments-vedettes en 1995: succès, échecs et incertitudes.